Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting

Gheyath K. Nasrallah, Soha R. Dargham, Farah Shurrab, Duaa W. Al-Sadeq, Hadeel Al-Jighefee, Hiam Chemaitelly, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Hadi M. Yassine, Mohamed G. Al Kuwari, Hamda Qotba, Hamad Eid Al Romaihi, Patrick Tang, Roberto Bertollini, Mohamed Al-Thani, Asmaa A. Althani, Laith J. Abu-Raddad
doi: https://doi.org/10.1101/2020.12.14.20248163

Data Availability

All relevant data are available within the manuscript.

Back to top
Posted December 14, 2020.
Download PDF
Data/Code
Email
Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
Gheyath K. Nasrallah, Soha R. Dargham, Farah Shurrab, Duaa W. Al-Sadeq, Hadeel Al-Jighefee, Hiam Chemaitelly, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Hadi M. Yassine, Mohamed G. Al Kuwari, Hamda Qotba, Hamad Eid Al Romaihi, Patrick Tang, Roberto Bertollini, Mohamed Al-Thani, Asmaa A. Althani, Laith J. Abu-Raddad
medRxiv 2020.12.14.20248163; doi: https://doi.org/10.1101/2020.12.14.20248163
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area